A more selective costimulatory blockade of the CD28-B7 pathway

Transplant International

Volumn 24, Issue 1, 2011, Pages 2-11

  Poirier, Nicolas ^a   Blancho, Gilles ^b,c,d   Vanhove, Bernard ^a,b,c,d  

^a TcL Pharma SAS   (France)

^b HÔTEL DIEU   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

autoimmunity; B7; CD28; costimulation; CTLA 4; immunointervention; regulatory T cells; transplantation

Indexed keywords

ABATACEPT; B7 ANTIGEN; BELATACEPT; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; T LYMPHOCYTE RECEPTOR; TGN 1412;

ACUTE GRAFT REJECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE STORM; HUMAN; KIDNEY TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TARGET CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES, REGULATORY;

EID: 78649990016     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01176.x     Document Type: Review

References (117)

1. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10: 1969.
2. Powell JD, Ragheb JA, Kitagawa-Sakakida S, Schwartz RH,. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol Rev 1998; 165: 287.
3. Hünig T,. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007; 95: 111.
4. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431.
5. Zheng Y, Manzotti CN, Liu M, et al. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004; 172: 2778.
6. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2: 17ra10.
7. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985.
8. Mellor AL, Munn DH,. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762.
9. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271.
10. Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162: 4983.
11. Tsai M, Ho H, Chien H, Ou-Yang P, Lee C, Lee P,. The role of B7 ligands (CD80 and CD86) in CD152-mediated allograft tolerance: a crosscheck hypothesis. Transplantation 2004; 77: 48.
12. Alegre ML, Frauwirth KA, Thompson CB,. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220.
13. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907.
14. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
15. Perez N, Karumuthil-Melethil S, Li R, Prabhakar BS, Holterman MJ, Vasu C,. Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation. J Immunol 2008; 180: 6566.
16. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ,. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111.
17. Butte MJ, Peña-Cruz V, Kim M, Freeman GJ, Sharpe AH,. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45: 3567.
18. Zhu X, Zhou Y, Wang M, Jin L, Yuan M, Li D,. Blockade of CD86 signaling facilitates a Th2 bias at the maternal-fetal interface and expands peripheral CD4+CD25+ regulatory T cells to rescue abortion-prone fetuses. Biol Reprod 2005; 72: 338.
19. Blazar BR, Sharpe AH, Taylor PA, et al. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. J Immunol 1996; 157: 3250.
20. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
21. Woodward JE, Bayer AL, Chavin KD, Blue ML, Baliga P,. T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade. Transplantation 1998; 66: 14.
22. Taylor PA, Noelle RJ, Blazar BR,. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311.
23. Bashuda H, Kimikawa M, Seino K, et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 2005; 115: 1896.
24. Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA,. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood 2002; 99: 1465.
25. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707.
26. Miller SD, Vanderlugt CL, Lenschow DJ, et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995; 3: 739.
27. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145.
28. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
29. Fife BT, Bluestone JA,. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166.
30. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097.
31. Guillot C, Ménoret S, Guillonneau C, et al. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood 2003; 101: 3325.
32. Séveno C, Coulon F, Haspot F, et al. Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation. Xenotransplantation 2007; 14: 25.
33. Pree I, Bigenzahn S, Fuchs D, et al. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2,3- dioxygenase. Transplantation 2007; 83: 663.
34. Davis PM, Nadler SG, Stetsko DK, Suchard SJ,. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin. Immunol 2008; 126: 38.
35. Carman JA, Davis PM, Yang W, et al. Abatacept does not induce direct gene expression changes in antigen-presenting cells. J Clin Immunol 2009; 29: 479.
36. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
37. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
38. Yin D, Fathman CG,. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. J Immunol 1995; 155: 1655.
39. Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh M,. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 1996; 62: 1942.
40. Zheng XX, Sayegh MH, Zheng XG, et al. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol 1997; 159: 1169.
41. Fan K, Wang H, Wei H, et al. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation 2007; 84: 746.
42. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97: 833.
43. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996; 93: 12439.
44. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309.
45. Kim KS, Denton MD, Chandraker A, et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol 2001; 158: 977.
46. Blazar BR, Taylor PA, Linsley PS, Vallera DA,. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994; 83: 3815.
47. Cross AH, Girard TJ, Giacoletto KS, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995; 95: 2783.
48. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL,. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997; 100: 1199.
49. Finck BK, Linsley PS, Wofsy D,. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225.
50. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 3348.
51. Ford ML, Koehn BH, Wagener ME, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007; 204: 299.
52. Williams MA, Onami TM, Adams AB, et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002; 169: 5387.
53. Ndejembi MP, Teijaro JR, Patke DS, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698.
54. Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001; 167: 5565.
55. Garidou L, Heydari S, Truong P, Brooks DG, McGavern DB,. Therapeutic memory T cells require costimulation for effective clearance of a persistent viral infection. J Virol 2009; 83: 8905.
56. Metz DP, Farber DL, Taylor T, Bottomly K,. Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation. J Immunol 1998; 161: 5855.
57. Hokey DA, Yan J, Hirao LA, et al. CLTA-4 blockade in vivo promotes the generation of short-lived effector CD8 T cells and a more persistent central memory CD4 T cell response. J Med Primatol 2008; 37 (Suppl. 2): 62.
58. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72: 377.
59. Bërsan T, Hausen B, Higgins JP, et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 2003; 75: 2106.
60. Boulday G, Ashton-Chess J, Bernard P, et al. Association of rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboons. Nephrol Dial Transplant 2004; 19: 1752.
61. Ossevoort MA, Ringers J, Kuhn EM, et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999; 68: 1010.
62. Hausen B, Klupp J, Christians U, et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001; 72: 1128.
63. Montgomery SP, Xu H, Tadaki DK, et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 2002; 74: 1365.
64. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637.
65. Hale DA, Dhanireddy K, Bruno D, Kirk AD,. Induction of transplantation tolerance in non-human primate preclinical models. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1723.
66. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
67. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
68. Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265.
69. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
70. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
71. Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17: 243.
72. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.
73. Lühder F, Huang Y, Dennehy KM, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197: 955.
74. Tacke M, Hanke G, Hanke T, Hünig T,. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239.
75. Lin C, Hünig T,. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33: 626.
76. Azuma H, Isaka Y, Li X, et al. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 2008; 8: 2004.
77. Kitazawa Y, Fujino M, Sakai T, et al. Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 362.
78. Müller N, Van Den Brandt J, Odoardi F, et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008; 118: 1405.
79. Gogishvili T, Langenhorst D, Lühder F, et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 2009; 4: e4643.
80. Schmidt J, Elflein K, Stienekemeier M, et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003; 140: 143.
81. Beyersdorf N, Gaupp S, Balbach K, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 445.
82. Tischner D, Weishaupt A, Van Den Brandt J, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006; 129: 2635.
83. Beyersdorf N, Ding X, Hünig T, Kerkau T,. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. Blood 2009; 114: 4575.
84. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018.
85. Ohresser M, Olive D, Vanhove B, Watier H,. Risk in drug trials. Lancet 2006; 368: 2205.
86. Schraven B, Kalinke U,. CD28 superagonists: what makes the difference in humans? Immunity 2008; 28: 591.
87. Waibler Z, Sender LY, Merten C, et al. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 2008; 3: e1708.
88. Soto PC, Stein LL, Hurtado-Ziola N, Hedrick SM, Varki A,. Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation. J Immunol 2010; 184: 4185.
89. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A,. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA 2006; 103: 7765.
90. Damle NK, Doyle LV, Grosmaire LS, Ledbetter JA,. Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes. J Immunol 1988; 140: 1753.
91. Gross JA, Callas E, Allison JP,. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 1992; 149: 380.
92. Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober J,. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83: 304.
93. Beyersdorf N, Ding X, Blank G, Dennehy KM, Kerkau T, Hünig T,. Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody. Blood 2008; 112: 4328.
94. Yu X, Albert MH, Martin PJ, Anasetti C,. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest 2004; 113: 1624.
95. Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK,. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 1704.
96. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR,. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000; 165: 5041.
97. Mirenda V, Jarmin SJ, David R, et al. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 2007; 109: 2968.
98. Dengler TJ, Szabo G, Sido B, et al. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation 1999; 67: 392.
99. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A,. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 2002; 73: 1310.
100. Haspot F, Villemain F, Laflamme G, et al. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99: 2228.
101. Guillonneau C, Séveno C, Dugast A, et al. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179: 8164.
102. Urakami H, Ostanin DV, Hünig T, Grisham MB,. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006; 38: 3244.
103. Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13: 519.
104. Haspot F, Séveno C, Dugast A, et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5: 2339.
105. Dugast A, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898.
106. Jang M, Pan F, Erickson LM, et al. A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway. Transplantation 2008; 85: 1051.
107. Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, et al. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008; 128: 1969.
108. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102: 564.
109. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 1972.
110. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S,. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5: 1235.
111. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303.
112. Read S, Malmström V, Powrie F,. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295.
113. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S,. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 2008; 105: 10113.
114. Friedline RH, Brown DS, Nguyen H, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009; 206: 421.
115. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18.
116. Greenwald RJ, Freeman GJ, Sharpe AH,. The B7 family revisited. Annu Rev Immunol 2005; 23: 515.
117. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390.